Petros Pharmaceuticals Inc
Petros Pharmaceuticals, Inc., a healthcare technology company, focuses on developing and licensing proprietary SaaS platform and Software as a medical device web application designed to assist pharmaceutical companies. The company is based in New York, New York.
Petros Pharmaceuticals Inc (PTPI) - Total Assets
Latest total assets as of March 2025: $17.61 Million USD
Based on the latest financial reports, Petros Pharmaceuticals Inc (PTPI) holds total assets worth $17.61 Million USD as of March 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Petros Pharmaceuticals Inc - Total Assets Trend (2018–2024)
This chart illustrates how Petros Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Petros Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Petros Pharmaceuticals Inc's total assets of $17.61 Million consist of 68.6% current assets and 31.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 34.9% |
| Accounts Receivable | $416.08K | 3.9% |
| Inventory | $1.35 Million | 12.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $3.20 Million | 30.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Petros Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Petros Pharmaceuticals Inc's current assets represent 68.6% of total assets in 2024, an increase from 23.6% in 2018.
- Cash Position: Cash and equivalents constituted 34.9% of total assets in 2024, up from 4.2% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 30.0% of total assets, a decrease from 68.0% in 2018.
- Asset Diversification: The largest asset category is intangible assets at 30.1% of total assets.
Petros Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Petros Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Petros Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Petros Pharmaceuticals Inc generates 0.48x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Petros Pharmaceuticals Inc is currently not profitable relative to its asset base.
Petros Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.53 | 1.60 | 0.13 |
| Quick Ratio | 0.53 | 1.46 | 0.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-12.67 Million | $ 6.68 Million | $ -44.83 Million |
Petros Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Petros Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.45 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -68.5% |
| Total Assets | $10.64 Million |
| Market Capitalization | $97.53K USD |
Valuation Analysis
Below Book Valuation: The market values Petros Pharmaceuticals Inc's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Petros Pharmaceuticals Inc's assets decreased by 68.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Petros Pharmaceuticals Inc (2018–2024)
The table below shows the annual total assets of Petros Pharmaceuticals Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $10.64 Million | -68.53% |
| 2023-12-31 | $33.80 Million | +4.24% |
| 2022-12-31 | $32.42 Million | -51.89% |
| 2021-12-31 | $67.39 Million | -3.53% |
| 2020-12-31 | $69.85 Million | +19.68% |
| 2019-12-31 | $58.37 Million | -12.74% |
| 2018-12-31 | $66.89 Million | -- |